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Abstract
Purpose of review—To review the recent developments in understanding the pathophysiology 
of heparin-induced thrombocytopenia (HIT) and in applying this knowledge to the treatment of 
patients with suspected and proven HIT.
Recent findings—HIT pathophysiology is dynamic and complex. HIT pathophysiology is 
initiated by four essential components – heparin (Hep), platelet factor 4 (PF4), IgG antibodies 
against the Hep–PF4 complex, and platelet FcγRIIa. HIT is propagated by activated platelets, 
monocytes, endothelial cells, and coagulation proteins. Insights into the unique HIT antibody 
response continue to emerge, but without consensus as to the relative roles of B cells, T cells, and 
antigen-presenting cells. Platelet activation via FcγRIIa, the sine qua non of HIT, has become 
much better appreciated. Therapy remains challenging for several reasons. Suspected HIT is more 
frequent than proven HIT, because of the widespread use of Hep and the inadequacies of current 
diagnostic tests and scoring systems. In proven HIT, approved treatments reduce but do not 
eliminate thrombosis, and have substantial bleeding risk. Rational novel therapeutic strategies, 
directed at the initiating steps in HIT pathophysiology and with potential combinations staged over 
time, are in various phases of development.
Summary—Progress continues in understanding the breadth of molecular and cellular players in 
HIT. Translation to improved diagnosis and treatment is needed.
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INTRODUCTION
Heparin-induced thrombocytopenia (HIT) is an uncommon but devastating complication of 
heparin (Hep) therapy. Paradoxically, anticoagulant medication and thrombocytopenia 
manifest not as bleeding, but rather as limb and life-threatening thrombosis. The thrombotic 
events are multifocal, involving veins, arteries, and the microvasculature.
In Table 1, we provide a framework for understanding HIT in the context of the major 
human thrombotic disorders. We define immune-mediated thrombocytopenia and 
thrombosis (ITT) as intravascular activation of blood cells and endothelial cells by 
components of the innate and adaptive immune systems, resulting in platelet–fibrin thrombi 
in large and small vessels of arterial and venous beds, as well as in the microvasculature, 
often concurrently. Each class of thrombosis, including ITT, has an annual US incidence of 
disease in excess of 500 000 cases per year. HIT is a paradigm for the ITT disorders, in that 
we have an advanced appreciation of many of the molecular and cellular players. (Note: ITT 
is distinct from ITP, an auto-immune bleeding disorder in which antibodies to platelet 
surface glycoproteins cause accelerated platelet clearance.) We have found this framework 
to be useful in examining the mechanisms and models in pathophysiology, as well as in the 
rational design of novel therapeutics.
PATHOPHYSIOLOGY
HIT is a dynamic and complex disorder. The initial steps of the most commonly recognized 
clinical form of HIT involve patient exposure to a form of Hep, followed by the 
development of IgG antibodies over 4–14 days directed to a complex of platelet factor 4 
(PF4) and Hep. The IgG antibodies activate platelets via FcgRIIa. Thrombin is generated 
and platelet–fibrin thrombi are formed (Fig. 1).
Since the essential initiating steps in HIT path-ophysiology were elucidated in the 1990s and 
early 2000s, attention has turned to the dissection of the complex steps encapsulated by the 
statements ‘IgG antibodies are formed to PF4/hep’ and ‘platelets are activated and thrombin 
is generated’.
Antibodies to the platelet factor 4 and heparin complex
Progress in the recent past has come from consideration of the origins of HIT antibody 
generation. Within days of treatment with Hep, IgG antibodies to Hep and PF4 are detected. 
The titers disappear for most patients after 90–120 days [1]. Some, but not all, HIT patients 
re-exposed to Hep manifest a detectable IgG again. Thus, the HIT IgG response is rightly 
called an atypical response. The outstanding questions are: what is the immunogen? What 
are the roles of antigen-presenting cells and T cells in the response, and which B cells 
produce the antibody?
It is generally accepted that the clinical manifestations of HIT are caused by antibodies that 
recognize an ultralarge complex (ULC) composed of Hep and PF4 tetramers. PF4 tetramers 
bind avidly to Hep and to cellular glycosaminoglycans (GAGs), an interaction that is central 
to the pathogenesis of HIT. Arepally and colleagues have used a murine immunization 
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model to investigate the immunogen [2,3]. Their data are compatible with the immunogen 
PF4 and Hep having a different molar ratio than the activating ULC. It remains to be 
determined how these data reflect specific B-cells and antigen-presenting cells. Greinacher 
and colleagues have identified PF4 bound to certain bacteria as initiating the generation of 
HIT-like antibodies [4–7]. Others have concordant data [8■]. PF4 bound to nucleic acids 
may also be immunizing [9■,10], as may interaction with several polyanions [11■]; further 
studies are needed. Wang and colleagues recently reported that HIT antibody generation had 
features of lost tolerance [12■■]. They also identified marginal zone B-cells as a potential 
source of the pathologic IgG [13■].
HIT antibodies bind preferentially to PF4 when Hep is present over a narrow molar ratio of 
reactants and activate platelets through FcγRIIA. Several epitopes of PF4 are important for 
pathogenic antibody binding [14,15], including two distinct antigenic sites: site 1 – residues 
after the third cysteine residue (beginning with proline-37); and site 2 – residues in the 
amino terminus and proline-34 [14]. Formation of ULC involves charge neutralization of 
PF4 with GAG [2,16] and clustering of PF4 molecules [16,17]. These data support a model 
in which Hep clustered PF4 residues to form neoepitopes where pathologic antibodies bind. 
We used single molecule binding with optical tweezers to reveal the difference between 
binding of a nonpathogenic anti-PF4 antibody (RTO) vs. pathologic anti-PF4/Hep antibody 
(KKO) [18,19■]. Greinacher and colleagues recently used circular dichroism to identify a 
Hep-bound PF4 conformation that is recognized by HIT antisera, and to provide insights 
into the dependence on GAG length and charge [20]. Further work, including three-
dimensional structural data, is required to definitively determine the nature of the 
neoepitopes created upon ULC formation.
The HIT antibodies in humans are polyclonal. In HIT mouse model systems, only the 
murine monoclonal antibody KKO has been proven to mirror the human HIT antibody. 
Asada et al. [21] identified a mouse IgG1 monoclonal HIT antibody used in ex-vivo HIT 
assays. Details of its preferential reactivity for PF4 and Hep over PF4 alone are needed. 
Progress in additional monoclonal HIT antibodies is anticipated.
As charge neutralization of PF4 by Hep is important for the formation of PF4–Hep 
complexes, Chudasama et al. [22] observed that other positively charged proteins, such as 
protamine, may similarly complex with Hep. Several groups have recently examined 
patients who have undergone cardiopulmonary bypass for antiprotamine–Hep antibodies and 
found that approximately 25–30% of such patients have demonstrable antibodies peaking 
10–30 days after surgery, which can activate platelets [23–25]. These antibodies do not 
cross-react with PF4–Hep ULC, and demonstrate a preference for protamine–Hep over 
protamine alone [24,26]. The clinical significance of these antibodies is not clear, although 
Bakchoul et al. [24] found an increase in early arterial thromboembolic events compared 
with controls (odds ratio 21.6; 95% confidence interval, 2.9–161). Further studies are 
required to better define the clinical implications of these antibodies.
How exactly the antigenic ULC is decorated with IgG antibodies in the pathologic immune 
complex (IC), and the connection between the IgG density and orientation along the ULC 
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responsible for Fcg receptor clustering on platelets and monocytes (see below) remain under 
investigation.
Platelet activation and thrombin generation
Propagation of HIT pathophysiologically follows from platelet activation (Fig. 2). 
Activation results in several consequences: platelets secrete more PF4, feeding back to 
create more antigen; platelets aggregate via activated integrin αIIbβ3; and platelets become 
procoagulant with a phosphatidylserine-positive surface for coagulation reactions and 
shedding of highly procoagulant microparticles [27–29].
The HIT IC signals through FcγRIIa to activate platelets. We have used both rational 
biological candidate approaches and unbiased genomic methods to increase the 
understanding of FcgRIIa-mediated platelet activation. We have established that protein 
tyrosine kinase Syk is the major FcγRIIa signaling node [30]; CalDAG-GEF1, ADP 
signaling, and 12-LOX have emerged as major determinants of FcγRIIa/Syk-mediated 
activation [31,32]. Platelet FcgRIIa was recently shown to be a transmembrane signaling 
adapter for outside-in αIIbβ3 signaling, quite distinct from its role as an IC receptor [33■]. 
Translation of these findings to HIT could be of substantial value.
There is considerable interindividual variation in platelet activation in response to IC 
agonists. For example, the gold-standard assays for HIT, the serotonin release assay and the 
Hep-induced washed platelet activation test, rely on ‘good/highly reactive’ healthy donor 
platelets, the characteristics of which have been empirical [34]. Rollin et al. [35■] have used 
candidate-gene methods to explore variation in HIT platelet reactivity. Among their findings 
is identification of single-nucleotide polymorphisms (SNPs) in CD148, a membrane protein 
tyrosine phosphatase, that influences platelet reactivity. Scarparo et al. [36■] examined HIT 
candidate-gene polymorphisms in FcγRIIa, PECAM1, and FcγRIIIa. Of note, a combination 
of FcgRIIa and PECAM1 SNP genotypes was significantly associated with HIT thrombosis. 
We have examined mRNAs and miRNAs differentially expressed by 154 healthy donors in 
HIT-like platelet aggregation assays [37]. For the first time, we have unbiased data 
identifying putative determinants of IC-mediated platelet activation; functional validation 
studies are in progress.
Thrombin generation follows coagulation initiation, most likely by tissue factor. Any one or 
two of three pathways lead to tissue factor exposure (Fig. 2). With a preexisting wound, 
surgical or traumatic, subendothelial tissue factor may already be present. Inflammation or 
atherosclerosis may have ‘preactivated’ endothelium and monocytes presenting tissue factor. 
Also, IgG immune complexes activate monocytes and ECs [38–42]. As with platelets, 
antigenic complexes between PF4 and GAGs can form on the surface of monocytes [43]. In 
fact, the amount of antigenic complex formed on monocytes is greater than on platelets. 
Chemical depletion of monocytes from a mouse model of HIT demonstrated potentiation of 
thrombocytopenia, but significant blunting of thrombosis [43]. Further, HIT antigenic 
complexes, binding to FcgRI and FcγRIIa, transduce specific signals to activate monocytes. 
These data provide mechanisms by which HIT IC may be prothrombotic via interactions 
with monocytes.
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Thrombin action is complex. Among its patho-physiological effects thrombin will feed back 
to activate platelets via PAR receptors, as well as cleave fibrinogen to fibrin. Platelet–fibrin 
thrombi formation is the final pathologic step (Fig. 2).
THERAPEUTICS
Current clinical practice will be summarized briefly first. In some HIT cases, thrombi form 
in macro-vascular beds with overt clinical symptoms, such as deep vein thrombosis/
pulmonary embolism, myocardial infarction, stroke, or limb ischemia. In other cases, the 
thrombi are in the microvasculature, with effects that are overt clinically (e.g., adrenal 
thrombosis followed by hemorrhage and skin necrosis) or remain subclinical. When Hep is 
present and PF4–Hep complexes are formed, disease persists. Cell-surface GAGs also bind 
PF4, and as this complex is recognized by the anti-PF4/Hep IgG, platelets and leukocytes 
are still being activated. Thus, simple withdrawal of Hep does not end the ITT. A non-Hep 
parenteral anticoagulant has been the mainstay of treatment.
In April 2014, there was one drug approved by the Food and Drug Administration and 
European Medicines Agency (EMA) for the treatment of HIT, the direct thrombin inhibitor 
(DTI) argatroban, and one drug approved for percutaneous coronary interventions in HIT, 
bivalirudin (also a DTI). Lepirudin is no longer manufactured. In some nations, dana-paroid, 
a mix of highly and minimally sulfated GAGs, is approved. Argatroban has been noted to 
have multiple limitations in practice [23,44], so new treatments are of value. The 
Clinicaltrials.gov site listed 29 entries under ‘heparin-induced thrombocytopenia’ in April 
2014. Only one new HIT therapy trial was recruiting, a study of oral FXa inhibitor 
rivaroxaban in HIT, NCT01598168.
Off-label use of fondaparinux has been the subject of expert opinion, clinical observation, 
and registries. Fondaparinux is a sulfated pentasaccharide that binds antithrombin, like 
unfractionated Hep and low molecular weight Heps. European Medicines Agency guidelines 
state, for ‘Patients with Heparin Induced Thrombocytopenia – Fondaparinux should be used 
with caution in patients with a history of HIT. The efficacy and safety of fondaparinux have 
not been formally studied in patients with HIT type II’ (www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/human/000403/WC500027746.pdf). The 
American College of Chest Physicians guidelines [45], and a recent review [46], call for 
more studies on the risks and benefits of fondaparinux in HIT. Clinicaltrials. gov has two 
registries of fondaparinux use with observations of HIT (NCT01304238 and NCT01004939) 
[47]. The primary issues are the rare reports of HIT initiated by fondaparinux or failing to 
improve with fondaparinux [48,49]. In our opinion, use of fondaparinux or non-Hep 
anticoagulants outside of a clinical trial in HIT is a local decision, much like the selection of 
antimicrobials for fever and neutropenia has been local. Therapy for suspected HIT should 
be individualized. Treatment decisions require clinical judgment. Adverse consequences 
include persistent thrombocytopenia, new or extended thrombosis, or major hemorrhage. 
Considerations for the use of approved DTIs, off-label fondaparinux, or non-Hep 
anticoagulants in HIT are listed below. Considerations in the individualized treatment of 
suspected HIT are as follows:
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(1) specific patients receiving Hep, for example, cardiovascular, orthopedic, 
medically ill, etc.;
(2) initial anticoagulation – use of unfractionated Hep, low molecular weight Hep, 
or fondaparinux;
(3) indication – for treatment, primary prophylaxis, or secondary prophylaxis;
(4) bleeding risk, including age, anatomical defects, or recent procedure;
(5) likelihood of new or additional interventional procedure;
(6) organ function (especially liver and kidney);
(7) concurrent medications;
(8) reversibility and half-life of the new anticoagulant;
(9) likelihood of proven HIT among those suspected of HIT;
(10) practice of proceeding to definitive HIT platelet activation assay;
(11) costs and insurance reimbursement;
(12) medicolegal environment for adverse consequences.
Recent clinical reports focus on estimating the proportion of suspected HIT patients that 
have true HIT, by use of an antibody detection method combined with one of the clinical 
scoring systems [50–60]. Currently, these approaches have inadequate positive predictive 
values to be generalizable [23]. More work is needed to make practical platelet activation 
assays more widely available in the general hospital clinical laboratory in a robust and 
timely way. Some progress in novel systems has been recently reported – multielectrode 
aggregometry [61], a lymphocyte cell line for HIT antibody activation [62■], determination 
of HIT-related platelet FcgRIIa proteolysis [63,64■], and a micro-patterned platelet 
activation assay [65■■].
Novel preclinical heparin-induced thrombocytopenia therapy
Every one of the approved, off-label, or clinical trial treatments is an anticoagulant geared to 
reduction of thrombin generation or action. Once HIT is established, thrombin is pathologic, 
or otherwise the approved DTIs would not work. However, continued thrombosis or major 
hemorrhage with DTIs remains problematic. It is unknown whether mono-therapy directed 
at thrombin, a late pathophysio-logical step, will be the basis for future approaches. Novel 
treatments targeted to earlier steps in the pathophysiology are in development (Fig. 2).
With our increased understanding of the structural nature of PF4–Hep complexes, there has 
been an interest in targeting these ULCs for the prevention and treatment of HIT. 
Therapeutics which prevent the formation of and promote ULC breakdown would represent 
a new approach [18,66,67].
A Hep-like molecule that has been investigated for disruption of PF4–GAG complexes is 
2,3,-O-desulfated heparin (ODSH). ODSH lacks most of the anticoagulation activity of Hep, 
but retains many anti-inflammatory properties [68]. Joglekar et al. [66] compared PF4– Hep 
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and PF4–ODSH complexes, and found that they both had similar light scattering and net 
charge properties, suggesting that both GAGs form somewhat similar complexes with PF4. 
However, PF4–Hep complexes formed in the presence of ODSH showed markedly reduced 
binding by antisera from HIT patients. It has also been demonstrated that, similar to 
danaparoid, ODSH decreases PF4 binding to platelets as well as activation of platelets by 
HIT antisera [67,68]. Taken together, these data suggest that some non-Hep GAGs may be 
of therapeutic value in HIT by disrupting the electrostatic interactions which drive ULC 
formation. Importantly, as the molar ratio of PF4 to GAG is important for the extent of 
complex formation and antibody recognition, empiric adjustment of dosing will be required 
to find the optimal dose at which the correct ratio will be achieved in vivo. A recent lucid 
summary of PF4 bioavailability in HIT was published, with implications for use of ODSH 
[34].
Another approach to disrupting ULCs is to antagonize PF4 tetramerization, which is a 
prerequisite for ULC formation. Our group screened over one million compounds in silico 
for their likelihood of binding to the dimer interface of PF4 [18]. Two of the candidate 
molecules inhibited tetramerization of PF4. Further, compounds PF4A01 and PF431-04 
completely inhibited ULC formation and promoted the breakdown of preformed ULC. 
Importantly, PF4As inhibited ULC formation at all PF4 : Hep ratios tested, and both 
antagonists prevented cellular activation by ULC and HIT antibodies. Although potency (as 
measured by IC50) of these initial antagonists are in the micromolar range and we seek 
compounds with submicromolar potency, they represent proof of concept of this approach 
for the prevention and treatment of HIT.
Prevention of platelet activation by the HIT IC is another promising approach. Antiplatelet 
agents in the current use have not been shown to be beneficial when used alone, such as 
cox1 inhibitors, P2Y12 blockers, or αIIbβ3 blockers. However, we have used our mouse 
model of HIT to demonstrate that inhibition of Syk can safely and effectively prevent HIT 
[30]. We used the Portola compound PRT060318. Subsequent studies identified the Rigel 
compound R406 to block platelet activation by the HIT IC via FcgRIIa [69]. In more recent 
work, we are investigating other intracellular platelet signaling molecules for blocking 
FcγRIIa-mediated platelet activation, while preserving hemostasis. We are also exploring 
combination therapies directed at several points in the early pathophysiology, for example, 
with PF4 antagonists and Syk inhibitors, in vivo in the HIT mouse model.
CONCLUSION
HIT remains a challenging clinical problem. Current pathophysiology studies are focused on 
the origin of the antibody response, the nature of the antigenic complex and pathologic 
epitopes, the mechanisms of interindividual differences in platelet activation, and the roles 
of monocytes and endothelial cells. Progress in therapy is hampered by the challenges of 
inadequate positive predictive value of antibody detection and clinical scores in suspected 
HIT, very limited availability of practical platelet activation assays, and the paucity of new 
agents in human clinical trials.
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KEY POINTS
• HIT is a complex and dynamic disorder, and a paradigm of the immune-
mediated thrombocytopenia and thrombosis disorders.
• HIT pathophysiology has an initiation phase, immunization to produce 
pathologic antibodies, then platelet activation by IgG–PF4–Hep immune 
complexes. The propagation phase feeds back to amplify the process and leads 
to thrombin generation culminating in platelet and fibrin thrombi.
• HIT therapy needs improvement that could come from better diagnostics in the 
form of practical platelet activation assays, and from combinations of rational 
therapeutics targeting early and late steps in pathophysiology.
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FIGURE 1. 
The multiple steps of HIT disorder. After immunization, there is initiation (upper left) 
culminating in IC-mediated platelet activation, then propagation (lower right) marked by the 
central roles of thrombin. Thrombin feeds back to enhance cellular activation and cleaves 
fibrinogen to fibrin. GAG, glycosaminoglycan; HIT, heparin-induced thrombocytopenia; IC, 
immune complex; PF4, platelet factor 4; ULC, ultralarge complex.
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FIGURE 2. 
A detailed view of HIT disorder and therapy. There are three potential routes to TF-
mediated thrombin generation, resulting in the final step of platelet–fibrin thrombi. On the 
left, the locus of current therapy directed at thrombin generation and action (T1) is compared 
with alternative and combination novel therapies geared to formation of the IC (T2) or 
inhibition of IC-mediated platelet activation (T3). Hep, heparin; HIT, heparin-induced 
thrombocytopenia; IC, immune complex; PF4, platelet factor 4; TF, tissue factor.
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Table 1
The four major classes of human thrombotic disorders
Classes of thrombotic disorders Selected examples
Atherothrombosis Coronary artery thrombosis/myocardial infarction; ischemic stroke; mesenteric artery 
thrombosis; limb artery thrombosis
Deep-vein thrombosis and pulmonary 
embolism
Lower extremity; upper extremity; cerebral venous; abdomen
Immune-mediated thrombocytopenia and 
thrombosis
HIT; antiphospholipid syndrome; sepsis syndrome; thrombosis from therapeutic monoclonal 
antibodies; thrombotic thrombocytopenic purpura
MCCATS Malformation, Cancer, Cardiac, Artificial surface, Trauma, Sickle cell disease
HIT is one of the immune-mediated thrombocytopenia and thrombosis disorders.
HIT, heparin-induced thrombocytopenia.
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